However, their hefty price tag is driving large increases in pharmaceutical spending despite a small number of patients treated. Payers have responded by imposing restrictions on use and by passing on higher costs to patients. This produces an innovation-access trade-off: high prices incentiv...
tafamidis氯苯唑酸cas594839-88-0 Catalog #Pkg SizePriceQuantityShopping CartR-KR-0290 1 ￥ 1 加入购物车 查看购物车 Datasheet MSDS COA 结构式 基本信息 产品描述 参考文献 相关文档 评论 外观 粉末或固体 分子量 308.116 溶解度 DMF DMSO CAS号 594839-88-0 质量控制 98% 储存条件 -20°C in ...
Tafamidis meglumine他发米帝司甲葡胺cas951395-08-7 Catalog #Pkg SizePriceQuantityShopping CartR-KR-0192 1 ￥ 1 加入购物车 查看购物车 Datasheet MSDS COA 结构式 基本信息 产品描述 参考文献 相关文档 评论 外观 粉末或固体 分子量 503.330 溶解度 DMF DMSO CAS号 951395-08-7 质量控制 98% 储存...
PharmaCompass also assists you with knowing theTafamidis API Priceutilized in the formulation of products.Tafamidis API Priceis not always fixed or binding as theTafamidis Priceis obtained through a variety of data sources. TheTafamidis Pricecan also vary due to multiple factors, including market con...
SizePriceStockQuantity Get Quotation Now Add to Cart Bulk Inquiry Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we ha...
Price: ￥3026.0/5mg ￥1566.0/2mg ￥13586.0/50mg ￥8336.0/25mg Purity: 98.0% Delivery: 2 Day Contact: Liu jia Email: 2130147988@qq.com DC Chemicals Limited China Product Name: PF-06291826(Tafamidis) Price: $400.0/100mg $700.0/250mg $1400.0/1g Purity: 98.0% Delivery: 3 Da...
4 but its high list price ($225 000) necessitates a complex process of insurance approval and financial assistance program applications.5 This study aimed to evaluate whether there are delays from diagnosis to treatment with tafamidis and whether socioeconomic factors are associated with unequal ...
However, their hefty price tag is driving large increases in pharmaceutical spending despite a small number of patients treated. Payers have responded by imposing restrictions on use and by passing on higher costs to patients. This produces an innovation-access trade-off: high prices incentiv...
However, their hefty price tag is driving large increases in pharmaceutical spending despite a small number of patients treated. Payers have responded by imposing restrictions on use and by passing on higher costs to patients. This produces an innovation-access trade-off: high prices incenti...
However, their hefty price tag is driving large increases in pharmaceutical spending despite a small number of patients treated. Payers have responded by imposing restrictions on use and by passing on higher costs to patients. This produces an innovation-access trade-off: high prices incentiv...